Stahl M
Innere Klinik (Tumorforschung) Westdeutsches Tumorzentrum, Universitätsklinikum Essen.
Praxis (Bern 1994). 1996 Mar 5;85(10):303-6.
Patients with esophageal cancer still have on unfavourable prognosis. After standard treatment, only 10% will survive five years. During the last years a lot of study groups intended to improve patient's prognosis by the use of multimodality treatment including chemotherapy. The concept of preoperative chemotherapy seems to be most promising. In the case of stage I and II cancer (potentially resectable tumors) multimodal therapy has not proved superior to surgery alone, so far. The results of well done phase III trials have to be waited for. Prognosis of patients with locally advanced tumors has been significantly improved by preoperative radiochemotherapy compared to surgery alone. In general, patients with localized esophageal cancer should be treated in experienced cancer centers within prospective trials.
食管癌患者的预后仍然不佳。经过标准治疗后，只有10%的患者能存活五年。在过去几年中，许多研究小组试图通过采用包括化疗在内的多模式治疗来改善患者的预后。术前化疗的概念似乎最有前景。对于I期和II期癌症（潜在可切除肿瘤）患者，迄今为止，多模式治疗尚未证明优于单纯手术。还需等待精心设计的III期试验结果。与单纯手术相比，术前放化疗显著改善了局部晚期肿瘤患者的预后。一般来说，局限性食管癌患者应在经验丰富的癌症中心接受前瞻性试验治疗。
